Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
Completed
Forest Laboratories
Phase 3
2011-08-01
The purpose of this study is to evaluate the safety and tolerability of nebivolol and
valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential
hypertension.
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
Completed
Forest Laboratories
Phase 3
2012-01-01
To evaluate the efficacy and safety of fixed-dose combination of nebivolol and valsartan
compared to monotherapy and placebo in patients with stage 1 and stage 2 hypertension.
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
Completed
Allergan Sales, LLC
Phase 4
2017-02-07
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood
pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement
therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
Completed
Trinity Hypertension & Metabolic Research Institute
Phase 4
2017-02-07
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood
pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement
therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.
A randomized,double-blind,double-dummy,active controlled,15 week study to evaluate the
effects of nebivolol and valsartan alone and in combination on 24-hour ambulatory cardiac
work and variability of heart rate-mean central systolic pressure product.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
